Context Therapeutics® and Tyligand Bioscience Reach ONA-XR Manufacturing Optimization Milestone


You May Also Like

Great Basin Scientific Closes $2.7 Million Offering of Units

SALT LAKE CITY, June 22, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (OTCQB:GBSN), ...

Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting

HAMPTON, N.J., June 05, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today ...